# Pizarra — PT-pseudo_4a4fedfc1f51 (task 1)

---

# Ronda 1

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_4a4fedfc1f51
Task: 1

Encounter: Urology - outpatient on 16 Feb 2025.
Referrer: Dr. M. Jansen (GP).
Type: Follow-up - PSA + MRI.

Clinical data (read-only — values loaded from the record):
  - 56-year-old male
  - PSA: 8.5 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.368 ng/mL²
  - PSA velocity: 2.14 ng/mL/yr
  - Prior PSA: 6.6 ng/mL
  - Prostate volume: 23.08 mL
  - Months since last PSA: 2
  - DRE findings: Nodus (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: None (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.87014735 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Not reported
  - Problem list / PMHx: none recorded
  - Current medication: None
  - Allergies: NKA
  - Additional notes: PSA 8.5 ng/mL. PI-RADS 5. PSAD 0.37. Prostate volume 23 mL. DRE nodus. csPCa 0.87.

Vitals: weight 78 kg, height 175 cm, BMI 25.5, BP 118/79 mmHg, HR 81 bpm. Smoking: Ex-smoker (22 pack-yr, quit 2009).

Chief complaint: A marked increase in serum prostate-specific antigen levels alongside concerning multiparametric magnetic resonance imaging results prompted this clinical evaluation.

History: Initial screening in late 2022 uncovered an elevated prostate-specific antigen reading, leading to ongoing serial assessments and symptom monitoring. He is a 56-year-old retired civil servant, widowed, and resides independently in a retirement community. Lower urinary tract complaints are negligible, scoring 5 on the IPSS questionnaire, and his regular cycling routine covers roughly 20 kilometres twice each week. Alcohol consumption averages 24 units weekly. He explicitly denies any urinary retention or haematuria. His medical background is otherwise clear, noting no active medications or systemic comorbidities. Past interventions include a surveillance colonoscopy and occasional over-the-counter analgesics for mild knee discomfort. A recent trip to southern France was documented, and he indicated that an Arabic interpreter would facilitate communication during this consultation.

Physical examination: DRE reveals a discrete Nodus within the left peripheral zone, while the remainder of the gland maintains uniform symmetry. General assessment shows no abnormalities; vital parameters are stable, respiratory sounds remain clear bilaterally, and peripheral lymph nodes are non-palpable.

Patient info: retired civil servant; Widowed; Lives in retirement community (independent unit).
Next of kin: Spouse / partner (primary contact).

Lifestyle: alcohol 24 units / week; exercise Cycling 2x/week, ~20 km; IPSS score: 5/35 (mild LUTS).

Recent other appointments: Gastroenterology — surveillance colonoscopy.
Admin: Interpreter (Arabic) requested for next visit.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status in the panel above is all the pathology information on record.]

## [2] STATISTICAL PRIOR (classifier)

**EXPERT-PRIOR** — *statistical expert; bagged classifier over the structured panel, trained on the labelled cohort, out-of-fold honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: BIOPSY
  p(biopsy = yes) = 0.91 +/- 0.06   (95% CI 0.80-1.00)

Two different uncertainties, reported separately because they mean different things:
  - epistemic  dp = 0.06  — the error bar on this number. It is the spread
    across bootstrap members: how much the answer would move with a different training sample.
  - aleatoric  H  = 0.42 of 1.00 — how mixed the outcome was among
    patients this model cannot tell apart. High H means the disagreement is in the data, not in
    the model, and more labelled cases would not fix it.

TIER 'firm': p +/- 1.96*dp does not cross the 0.5 threshold. Treat it as a strong prior that should only be overturned by explicit contradicting evidence. Measured accuracy in this tier on the labelled cohort: 1.0 over 28 cases.

Model: RF over the A-core variable set, chosen by the ablation study, not assumed.
Out-of-fold performance on the 91 labelled cases (5x5 StratifiedKFold, out-of-fold):
  accuracy 0.714 (majority-class baseline 0.615), AUC 0.789, F1(yes) 0.78.
Variables it could not read for this patient: none.

It has read ONLY the structured panel and the parsed record. It has not reasoned about the
prose of the mpMRI report, and it does not know what this patient's management plan is.

## [3] GUIDELINE CRITERION FOR THIS SITUATION

**EXPERT-PROTOCOL** — *protocol expert; applies the guideline criterion for this patient's clinical situation*

CLINICAL SITUATION: biopsy-naive.

CRITERION VERDICT: BIOPSY.

The criterion: Biopsy when the mpMRI shows a PI-RADS 3 or higher lesion; defer when PI-RADS is 1-2.

In the labelled cohort this criterion matched the reading urologist in every one of the 24 biopsy-naive cases (20 of them PI-RADS 4-5 and biopsied, 4 of them PI-RADS 2 or unreadable and deferred).

Track record of this criterion on the labelled cohort: 24 of 24 cases matched the reading urologist. Departing from it needs a specific finding from a retrieved document, named explicitly - not a restatement of the panel numbers it already used.

Like the statistical prior, this expert has read ONLY the visible panel. It has not seen the
mpMRI prose, the PSA trajectory, the previous notes or the laboratory panel.

## [4] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

Frozen foundation-model embeddings on file for this patient: MRI image (1 vector).
The raw vectors are never shown; only a compact score would be.

No calibrated head is deployed for the biopsy decision, so no score was produced. The probe that measured this modality for task 1 reported AUC 0.43 (at or below chance), which is why nothing is being asserted here.

Bottom line for the chair: the image-embedding route contributes NO usable evidence for this
biopsy decision. Decide on the structured panel, the retrieved documents and the guidelines.
Do not cite imaging-embedding support in the reasoning, and do not let the absence of a score
count as a negative finding.

## [5] AGENDA (round 1)

**MODERATOR** — *moderator; owns the agenda and decides whether the conference may close*

AGENDA FOR ROUND 1. These are the documents this case needs opened, and the question each one must answer. Open these and nothing else unless a named question requires it.

  - radiology_report (get_mri_report) -> Does the mpMRI report provide sufficient detail on the lesion size and comparison to earlier studies?
  - psa_trend (get_psa_trend) -> What is the serial PSA trend beyond the headline value of 8.5 ng/mL?
  - previous_notes (get_previous_notes) -> What is the prior management context, including prior grade and surveillance pathway?

This case hinges on integrating the high-risk PI-RADS 5 finding with the statistical prior and guideline recommendation. The decision requires retrieving the specific details from the MRI, PSA history, and prior management to confirm the protocol's application. Agenda capped at 3 documents; dropped laboratory_results.

## [6] GAPS AND DOUBTS (round 1)

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
The statistical prior only weighed the structured panel, which includes PSA (8.5 ng/mL), PI-RADS 5, PSA density (0.368 ng/mL²), and prostate volume (23.08 mL). It cannot account for the clinical context, such as the patient's history of mild LUTS (IPSS 5/35), his ex-smoker status, or the specific interpretation of the DRE finding ("Nodus").

WHY THE SUGGESTION COULD BE WRONG
The prior suggests biopsy based on a high probability (0.91), but the aleatoric uncertainty (H=0.42) indicates significant data variability. The guideline criterion is PI-RADS $\ge 3$, which is met (PI-RADS 5). However, the prior does not account for the potential for overdiagnosis, as the guideline discussion suggests, which could lead to an unnecessary biopsy if the true cancer risk is low.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
radiology report - Does the mpMRI report provide sufficient detail on the lesion size and comparison to earlier studies?
psa_trend - What is the serial PSA trend beyond the headline value of 8.5 ng/mL?
previous_notes - What is the prior management context, including prior grade and surveillance pathway?
previous_notes - What is the prior management context, including prior grade and surveillance pathway?
previous_notes - What is the prior management context, including prior grade and surveillance pathway?
GUIDELINE ANCHOR
The guideline states that a PI-RADS $\ge 3$ lesion triggers biopsy, and the track record confirms this criterion matches the reading urologist.

## [7] EVIDENCE REPORT (round 1)

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
get_mri_report
Report Metadata
Source: Radiology Unit, Maastricht UMC+
Date Issued: 2025-02-10
Modality: Multiparametric MRI of the Prostate
Referred for: PSA elevation to 8.5 ng/mL with a palpable nodule on digital rectal exam.
FINDINGS: Glandular volume registers at 23.08 mL. T2 sequences highlight a circumscribed hypointense focus within the left mid-gland peripheral zone, spanning 12 x 10 x 9 mm. Diffusion-weighted acquisitions show profound restriction with matching low apparent diffusion coefficient values. Dynamic contrast-enhanced phases demonstrate early focal enhancement contrasting against adjacent tissue. Extracapsular spread and seminal vesicle involvement are absent. Pelvic lymph nodes and bone marrow appear normal.
IMPRESSION: PI-RADS 5 lesion in the left mid-gland peripheral zone. PSAD 0.368 ng/mL/mL. csPCa predicted probability 0.87014735.

get_psa_trend
[{"date": "Sep 2022", "val": 8.1}, {"date": "Dec 2023", "val": 5.6}, {"date": "Feb 2025", "val": 8.5}]

get_previous_notes
[{"date": "19 Oct 2024", "author": "Dr. M. Jansen (GP)", "text": "21 Jun 2024 - Dr. M. Jansen (GP): A routine clinical review took place following a December 2023 PSA reading of 6.6 ng/mL. The upward clinical trend was addressed alongside a confirmation that his medication regimen has not changed. A follow-up PSA measurement was arranged for early 2025 to track the ongoing progression."}, {"date": "21 Jun 2024", "author": "Dr. M. Jansen (GP)", "text": "19 Oct 2024 - Dr. M. Jansen (GP): A scheduled review focused on recent laboratory values and overall symptom load. Lower urinary tract complaints remain minimal, reflected by an IPSS score of 5, while his preference for cycling twice weekly continues without issue. Weekly alcohol intake averages 24 units, and he maintains independent living arrangements within a retirement community setting."}]

NOT RETRIEVED
laboratory_results
The full laboratory panel was not retrieved because the moderator's agenda did not explicitly require it, and no specific question was raised regarding PSA kinetics, infection, or renal function.

WHAT THE EVIDENCE SUPPORTS
FOR sampling this patient now:
- mpMRI report: PI-RADS 5 lesion in the left mid-gland peripheral zone, measuring 12 x 10 x 9 mm, with profound diffusion restriction.
- psa_trend: Serial PSA trend shows an increase from 5.6 ng/mL (Dec 2023) to 8.5 ng/mL (Feb 2025).

AGAINST sampling this patient now:
- previous_notes: No prior biopsy grade or explicit mention of an active surveillance protocol requiring a protocol biopsy.

WHERE THIS LEANS
The high-risk PI-RADS 5 finding, combined with a rising PSA trend, strongly supports the guideline criterion for biopsy.
LEAN: biopsy

[Opened in this round: radiology_report, psa_trend, previous_notes. Open on the board so far: radiology_report, psa_trend, previous_notes.]

## [8] CLOSING CHECK (round 1)

**MODERATOR** — *moderator; owns the agenda and decides whether the conference may close*

THE CONFERENCE MAY CLOSE.

Positions on the table: prior=yes, protocol=yes, evidence=yes.
Consensus: yes — unanimous among those who took a position.
Agenda: requested ['radiology_report', 'psa_trend', 'previous_notes']; opened ['radiology_report', 'psa_trend', 'previous_notes']; still missing nothing.

The retrieved evidence (PI-RADS 5 lesion, rising PSA trend, and lack of prior biopsy information) strongly supports the guideline criterion for biopsy.

The chair decides on the record as it stands.

## [9] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: BIOPSY   (confidence: clear)

The decision to biopsy is supported by convergence across all inputs. The PI-RADS 5 finding was decisive, aligning with the guideline criterion for biopsy. This was reinforced by the rising PSA trend, which was retrieved from the PSA history, and the absence of any prior biopsy information. The statistical prior also strongly suggested biopsy, leading to a clear consensus.

Variables that carried weight: age=important, psa=important, vol=noted, psad=important, pirads=decisive, comorbidity=noted
Sections revealed: radiology_report, psa_trend, previous_notes
